Loading…
Loading…
RXRX does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for RXRX and 80,000+ other tickers.
See exactly how RXRX's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for RXRX and 80,000+ other tickers.
Recursion Pharmaceuticals, Inc. operates as a biotechnology firm currently in its clinical development phase. The company's mission is to revolutionize drug discovery by decoding biological processes, utilizing an integrated approach that combines technological innovations across biology, chemistry, automation, data science, and engineering. Their developmental pipeline features several clinical-stage compounds: REC-994, which is advancing through Phase IIa trials for cerebral cavernous malformation; REC-3599, currently in Phase I trials for GM2 gangliosidosis; REC-2282, aimed at treating…
Amova Asset Management Americas Inc. decreased its position in shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) by 12.9% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 5,419,221 shares of the company's stock after selling 801,804 shares during the period. Amova Asset
In the closing of the recent trading day, Recursion Pharmaceuticals (RXRX) stood at $2.89, denoting a -1.87% move from the preceding trading day.
In the most recent trading session, Recursion Pharmaceuticals (RXRX) closed at $3.34, indicating a +1.21% shift from the previous trading day.
Recursion Pharmaceuticals has yet to prove that its approach to developing medicines is superior. Sarepta Therapeutics will struggle to shake off safety concerns about its most important therapy.
Recursion Pharmaceuticals (RXRX) closed the most recent trading day at $3.72, moving 3.13% from the previous trading session.